ID   K562/A*0201
AC   CVCL_B7RM
DR   Wikidata; Q112929937
RX   PubMed=11730845;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 4931; HLA-A (allele A*02:01).
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 02-05-24; Version: 5
//
RX   PubMed=11730845; DOI=10.1016/S0022-1759(01)00499-9;
RA   Britten C.M., Meyer R.G., Kreer T., Drexler I., Wolfel T., Herr W.;
RT   "The use of HLA-A*0201-transfected K562 as standard antigen-presenting
RT   cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.";
RL   J. Immunol. Methods 259:95-110(2002).
//